Anticoagulants in obstetrics
https://doi.org/10.21518/2079-701X-2018-7-140-145
Abstract
During pregnancy, venous thromboembolic events (VTE) (absolute VTE rates) are relatively low and occur with a frequency of approximately 0.06% or 0.5–2.2 per 1000 deliveries [1–3]. Nevertheless, VTE is one of the key causes of maternal mortality (on top of that, conditionally avoidable). It is believed that during pregnancy the risk of VTE is increased dramatically - about three to tenfold [4] compared to non-pregnant women, provided that most of the women do not have VTE before pregnancy. According to some authors [5–6], in the postpartum period the risk of VTE is increased 15– to 35-fold compared to age-matched non-pregnant women and remains elevated for 3–6 months after delivery.
About the Author
A. V. Murashko
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)
Russian Federation
MD, Prof.
Russian Federation
MD, Prof.
References
1. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med, 2005, 143: 697–706.
2. Bates MS, Middeldorp S, Rodger M, James AH, Greer I Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis, 2016, 41: 92–128.
3. Ozolinya LA. Prevention of venous thrombosis and thromboembolism in obstetrics and gynaecology. Rossiyskiy Vestnik Akushera-Ginekologa, 2011, 11 (5): 98-101
4. Pomp ER, Lenselink AM, Rosendaal FR, Doggen CJ. Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost, 2008, 6: 632–637.
5. Anderson FA Jr, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and casefatality rates of deep vein thrombosis and pulmonary embolism. The Worcester Study. Arch Intern Med, 1991, 151: 933–938.
6. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton LJ 3rd. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med, 2005, 143: 697–706.
7. Gherman RB, Goodwin TM, Leung B et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol, 1999, 94: 730–734.
8. Chisaka H, Utsunomiya H, Okamura K, et al. Pulmonary thromboembolism following gynecologic surgery and cesarean section. Int J Gynaecol Obstet, 2004, 84: 47–53.
9. Kamel H, Navi BB, Sriram N, Hovsepian DA, Devereux RB, Elkind MS. Risk of a thrombotic event after the 6-week postpartum period. N Engl J Med, 2014, 370: 1307–1315.
10. Koroleva NS, Murashko AV. Anticoagulation therapy during pregnancy. Arkhiv Akusherstva i Ginekologii Im. V.F. Snegireva, 2014, 1 (2): 41-43.
11. Murashko AV. Prevention of venous thromboembolic events in pregnancy. Ginekologiya, 2008, 10 (4): 71-74.
12. Chan WS, Rey E, Kent NE, VTE in Pregnancy Guideline Working Group, Chan WS, Kent NE, Rey E, Corbett T, David M, Douglas MJ, Gibson PS, Magee L, Rodger M, Smith RE. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can, 2014, 36(6): 527–553.
13. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 37a. Reducing the risk of thrombosis and embolism during pregnancy and the puerperium. 2015. https: // www.rcog.org.uk/en/guidelinesresearch-services/guidelines/ gtg37a/. Accessed 10 June 2015.
14. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO, American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e691S– e736S.
15. Kearon C, Akl EA, Comerota A, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR, American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl): e419S– e3494S.
16. Kirienko AI, Leontyev SG, Lebedev IS, Seliverstov EI. Prevention of venous thromboembolic events in surgical practice. Consilium Medicum, 2006, 8 (7): 78-80.
17. Prevention of venous thromboembolic events in obstetrics and gynaecology, Ministry of Health of the Russian Federation, 2014.
18. Makatsaria AD, Bitsadze VO, Khizroeva D.H., Nemirovsky VB, Gadaeva ZK, Akinshina SV. Thromboprophylaxis in pregnant women with thrombophilia and thromboses in anamnesis. Byulleten Sibirskogo Otdeleniya Rossiyskoy Akademii Meditsinskikh Nauk, 2013, 33 (6): 99-109.
19. Khalafallah AA, Ibraheem ARO, Qiong Yue Teo, AlBarzan AM, Parameswaran R, Hooper E, Pavlov T, Dennis AE, Hannan T Clinical Study. Review of Management and Outcomes in Women with Thrombophilia Risk during Pregnancy at a Single Institution. Hindawi Publishing Corporation ISRN Obstetrics and Gynecology, 2014, 2014: Article ID 381826.
20. Carroll R, Rebarber A, Booker W, Fox N, Saltzman D, Lam-Rachlin J & Gupta S Double versus single thrombophilias during pregnancy. J Matern Fetal Neonatal Med, 2017 Jul 16: 1-4.
21. Larciprete G, Rossi F, Deaibess T, Brienza L, Barbati G, Romanini E, Gioia S, Cirese E Double inherited thrombophilias and adverse pregnancy outcomes: Fashion or science? Journal of Obstetrics and Gynaecology Research, 2010 October, 36(Issue 5): 996–1002.
22. Hassouna A, Allam H. Anticoagulation of pregnant women with mechanical heart valve prosthesis: a systematic review of the literature (2000–2009). J Coagul Disorders, 2010, 2: 81–88.
23. Schaefer C, Hannemann D, Meister R et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost, 2006, 95: 949–957.
24. Tang A-W, Greer I. A systematic review on the use of the new anticoagulants in pregnancy. Obstet Med, 2013, 6: 64–71.
25. Elsaigh E, Thachil J, Nash MJ, Tower C, Hay CR, Bullough S, Byrd L. The use of fondaparinux in pregnancy. Br J Haematol, 2014. doi: 10.1111/ bjh.13147.
26. Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, Ageno W. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a metaanalysis of the literature. J Thromb Haemost, 2013, 11: 270–281.
27. Lim W, Dentali F, Eikelboom JW, Crowther MA. Metaanalysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med, 2006, 144(9): 673–684.
28. Brill-Edwards P, Ginsberg JS, Gent M, Hirsh J, Burrows R, Kearon C et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Eng J Med, 2000, 343: 1439–1444.
29. De Stefano V, Martinelli I, Rossi E, Battaglioli T, Za T, Mannuccio MP et al. The risk of recurrent venous thromboembolism in pregnancy and puerperium without antithrombotic prophylaxis. Br J Haematol, 2006, 135: 386–391.
30. Pabinger I, Grafenhofer H, Kaider A, Kyrle PA, Quehenberger P, Mannhalter C et al. Risk of pregnancy-associated recurrent venous thromboembolism in women with a history of venous thrombosis. J Thromb Haemost, 2005, 3: 949–954.
31. Greer IA, Nelson Piercy C. Low molecular weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood, 2005, 106: 401–407.
32. Romualdi E, Dentali F, Rancan E, Squizzato A, Steidl L, Middeldorp S, Ageno W. Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a metaanalysis of the literature. J Thromb Haemost, 2013, 11: 270–281.
Review
For citations:
Murashko AV. Anticoagulants in obstetrics. Meditsinskiy sovet = Medical Council. 2018;(7):140-145. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-140-145
Views:
863
Email this article 